OSUR

Over the past six months (March 2026 - September 2026), OraSure's stock was impacted by several events. In March 2026, negative movements followed a letter from activist investor Altai Capital Management calling for a strategic review. April saw a slight negative movement after a new board appointment and another negative movement ahead of Q1 2026 earnings. May 2026 brought a positive movement with the announcement of Q1 2026 financial results. In June, FDA clearance for expanded STI testing access led to a positive movement. July saw a slight negative movement after Emergency Use Authorization for its Second Generation Ebola Test, followed by a positive movement ahead of Q2 2026 earnings. August 2026 saw a negative movement with the announcement of Q2 2026 financial results. In September, an investor group disclosed a SCHEDULE 13D filing, indicating they may seek board seats and a possible sale.